Rockefeller grants commercial license for the development of monoclonal antibodies for treatment of COVID-19
February 3, 2021The treatment, a combination of two antibodies, has been shown highly capable of neutralizing SARS-CoV-2 in preclinical studies. Researchers hope it will give countries around the world, including developing countries, a way to control the rampant disease.
Read more